US-China trade talks stalled as both sides refuse to budge on tariffs, fueling economic uncertainty.
Vertex Pharmaceuticals reports mixed Q1 2025 results, with revenue rising but missing expectations, and faces intellectual property issues in Russia, but raises 2025 guidance and sees strong uptake for its new pain drug.
U.S. intelligence memo contradicts Trump's claims about Venezuelan gang, undermining administration's justification for rapid deportations.
US-China trade talks stalled as both sides refuse to budge on tariffs, fueling economic uncertainty.
Vertex Pharmaceuticals reports mixed Q1 2025 results, with revenue rising but missing expectations, and faces intellectual property issues in Russia, but raises 2025 guidance and sees strong uptake for its new pain drug.
U.S. intelligence memo contradicts Trump's claims about Venezuelan gang, undermining administration's justification for rapid deportations.